Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07223983 · ClinicalTrials.gov registry record · Phase 1
Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)
A Phase 1 study, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT07223983 is a Phase 1 study that is actively recruiting participants, run by Yale University. The registered enrollment target is 10 participants.
The verdict
NCT07223983, a Phase 1 study, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate the feasibility of treating Alcohol Use Disorder with Semaglutide after metabolic and bariatric surgery in adults with overweight or obesity.
Interventions
- DRUG Semaglutide 1.0 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-03-06 |
| Est. Completion | 2026-10-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07223983
The ClinicalTrials.gov registry entry for NCT07223983 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Semaglutide 1.0 mg is the first listed.
NCT07223983 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07223983 about?
NCT07223983 is a clinical study titled "Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)". The purpose of this research study is to evaluate the feasibility of treating Alcohol Use Disorder with Semaglutide after metabolic and bariatric surgery in adults with overweight or obesity.
What is the current status of trial NCT07223983?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2026-03-06. Estimated completion is 2026-10-31.
What interventions are being tested in trial NCT07223983?
The interventions under investigation include: Semaglutide 1.0 mg (DRUG).
Who is sponsoring clinical trial NCT07223983?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.